T1	Participants 0 146	Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer
T2	Participants 157 291	To compare the toxicity between hypofractionation vs. conventional fractionation schedules in patients with high-risk prostate cancer.
T3	Participants 354 366	168 patients
T4	Participants 386 417	receive either hypofractionated
T5	Participants 473 503	or conventionally fractionated
T6	Participants 543 620	three-dimensional conformal radiotherapy to the prostate and seminal vesicles
